Full Press Release Details
Provides Business Update and Reports First Quarter 2025 Financial Results
secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash
Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership
with major cancer center
seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets
call and webcast to be held today, May 15th, at 8:30 AM EDT
YORK, May 15, 2025 - PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage
medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update
for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"),
and reported financial results for the quarter ended March 31, 2025.
webcast will take place on Tuesday, May 15, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's
website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184
and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed
Business Update" to join.
the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's
website at pavmed.com.
having stabilized its corporate structure and balance sheet, is well positioned to aggressively execute its strategic vision as a diversified
commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model," said
Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Both Lucid and Veris are now well-capitalized
through key upcoming milestones and we expect PAVmed to directly benefit from their success. We have an established track record of seeking
value throughout the life sciences sector, initially expanding from medical devices into diagnostics with Lucid, and then into digital
health with Veris. We now see a significant opportunity to leverage PAVmed's infrastructure and further diversify its portfolio
into the biopharma sector. We are actively evaluating attractive clinical and late preclinical-stage assets and hope to launch a subsidiary
in this sector in the near future."
from the first quarter and recent weeks:
Diagnostics (link to press release) recognized $0.8 million in EsoGuard Esophageal DNA Test revenue for
1Q25 and processed 3,034 EsoGuard tests.
Condensed Consolidated Statement of Operations (Unaudited)
| For the three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (in thousands except per-share amounts) | ||||||||
| Revenue | $ | 8 | $ | 1,010 | ||||
| Operating expenses | 5,454 | 15,046 | ||||||
| Other (Income) Expense | (24,069 | ) | 4,476 | |||||
| Net (Income) Loss | (18,623 | ) | 18,512 | |||||
| Net income (loss) per common share, diluted | $ | 0.34 | $ | (2.62 | ) | |||
| Net income (loss) attributable to common stockholders | 17,695 | (22,788 | ) | |||||
| Preferred Stock dividends and deemed dividends | 1,273 | 7,576 | ||||||
| Net income (loss) as reported | 18,968 | (15,212 | ) | |||||
| Adjustments: | ||||||||
| Depreciation and amortization expense 1 | 43 | 586 | ||||||
| Interest expense, net 2 | (4 | ) | (56 | ) | ||||
| NCI ownership share of Interest and Depreciation adjustments | - | (131 | ) | |||||
| EBITDA | 19,007 | (14,813 | ) | |||||
| Other non-cash or financing related expenses: | ||||||||
| Stock-based compensation expense 3 | 930 | 1,882 | ||||||
| Operating expenses issued in stock 1 | 50 | 23 | ||||||
| Change in FV equity method investments | (21,004 | ) | - | |||||
| Change in FV convertible debt 2 | 49 | 2,163 | ||||||
| Loss on debt extinguishment 2 | 58 | 369 | ||||||
| Debt modification expense | - | 2,000 | ||||||
| NCI ownership share of non-GAAP adjustments | - | (239 | ) | |||||
| Non-GAAP adjusted (loss) | $ | (910 | ) | $ | (8,615 | ) | ||
| Non-GAAP shares outstanding, basic and diluted | 13,876 | 8,695 | ||||||
| Non-GAAP adjusted (loss) income per share, basic and diluted | $ | (0.07 | ) | $ | (0.99 | ) |
Included in general and administrative expenses in the financial statements.
Included in other income and expenses.
Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by
category within operating expenses for the non-GAAP Net operating expenses:
Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses
| (in thousands except per-share amounts) | For the three months ended March 31, | |||||||
| 2025 | 2024 | |||||||
| Cost of revenue | $ | 36 | $ | 1,744 | ||||
| Stock-based compensation expense 3 | - | (36 | ) | |||||
| Net cost of revenue | 36 | 1,708 | ||||||
| Amortization of acquired intangible assets | - | 372 | ||||||
| Sales and marketing | 247 | 4,311 | ||||||
| Stock-based compensation expense 3 | (45 | ) | (403 | ) | ||||
| Net sales and marketing | 202 | 3,908 | ||||||
| General and administrative | 4,384 | 6,678 | ||||||
| Depreciation expense | (43 | ) | (214 | ) | ||||
| Operating expenses issued in stock | (50 | ) | (23 | ) | ||||
| Stock-based compensation expense 3 | (796 | ) | (1,078 | ) | ||||
| Net general and administrative | 3,495 | 5,363 | ||||||
| Research and development | 787 | 1,941 | ||||||
| Stock-based compensation expense 3 | (89 | ) | (365 | ) | ||||
| Net research and development | 698 | 1,576 | ||||||
| Total operating expenses | 5,454 | 15,046 | ||||||
| Depreciation and amortization expense | (43 | ) | (586 | ) | ||||
| Operating expenses issued in stock | (50 | ) | (23 | ) | ||||
| Stock-based compensation expense 3 | (930 | ) | (1,882 | ) | ||||
| Net operating expenses | $ | 4,431 | $ | 12,555 |
PAVmed and its Subsidiaries
Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors.
Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets
the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device-the first and only
commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other
subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring
using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently
developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the
Veris Cancer Care Platform.
more and for more information about PAVmed, please visit pavmed.com.
more information about Lucid Diagnostics, please visit luciddx.com.
more information about Veris Health, please visit verishealth.com.
press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements
that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's
and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's
and Lucid's common stock; PAVmed's Series Z warrants; general economic and market conditions; the uncertainties inherent
in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory
submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical
and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance
of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional
funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult
to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and
Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual
Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors"
in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention
or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions,
or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
and Lucid Diagnostics